Selection of phages and conditions for the safe phage therapy against <i>Pseudomonas aeruginosa</i> infections

Victor Krylov; Olga Shaburova; Elena Pleteneva; Sergey Krylov; Alla Kaplan; Maria Burkaltseva; Olga Polygach; Elena Chesnokova

doi:10.1007/s12250-014-3546-3

February 2015

Victor Krylov, Olga Shaburova, Elena Pleteneva, Sergey Krylov, Alla Kaplan, Maria Burkaltseva, Olga Polygach and Elena Chesnokova. Selection of phages and conditions for the safe phage therapy against Pseudomonas aeruginosa infections[J]. Virologica Sinica, 2015, 30(1): 33-44. doi: 10.1007/s12250-014-3546-3

Citation: Victor Krylov, Olga Shaburova, Elena Pleteneva, Sergey Krylov, Alla Kaplan, Maria Burkaltseva, Olga Polygach, Elena Chesnokova. Selection of phages and conditions for the safe phage therapy against Pseudomonas aeruginosa infections .VIROLOGICA SINICA, 2015, 30(1) : 33-44. http://dx.doi.org/10.1007/s12250-014-3546-3

Selection of phages and conditions for the safe phage therapy against Pseudomonas aeruginosa infections

cstr: 32224.14.s12250-014-3546-3

通讯作者： Victor Krylov, krylov.mech.inst@mail.ru;
收稿日期： 2014-11-15
录用日期： 2015-01-30
出版日期： 2015-02-05

Selection of phages and conditions for the safe phage therapy against Pseudomonas aeruginosa infections

I.I. Mechnikov Research Institute for Vaccines & Sera, RAMS, Moscow 105064, Russian

Corresponding author: Victor Krylov, krylov.mech.inst@mail.ru
Received Date: 15 November 2014
Accepted Date: 30 January 2015
Published Date: 05 February 2015

Abstract

The emergence of multidrug-resistant bacterial pathogens forced us to consider the phage therapy as one of the possible alternative approaches to treatment. The purpose of this paper is to consider the conditions for the safe, long-term use of phage therapy against various infections caused by Pseudomonas aeruginosa. We describe the selection of the most suitable phages, their most effective combinations and some approaches for the rapid recognition of phages unsuitable for use in therapy. The benefi ts and disadvantages of the various different approaches to the preparation of phage mixtures are considered, together with the specifi c conditions that are required for the safe application of phage therapy in general hospitals and the possibilities for the development of personalized phage therapy.

References
1. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. 2011. Phage treatment of human infections. Bacteriophage, 1: 66-85.
  doi: 10.4161/bact.1.2.15845
2. Alemayehu D, Casey PG, McAuliffe O, Guinane CM, Martin JG, Shanahan F, Coffey A, Ross RP, Hill C. 2012. Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio, 3: e00029-e00012.
3. Briers Y, Walmagh M, Grymonprez B, Biebl M, Pirnay JP, Defraine V, Michiels J, Cenens W, Aertsen A, Miller S, Lavigne R. 2014. Art-175 is a highly efficient antibacterial against multidrug-resistant strains and persisters of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 58: 3774-3784.
  doi: 10.1128/AAC.02668-14
4. Burkal'tseva MV, Pleteneva EA, Shaburova OV, Kadykov VA, Krylov VN. 2006. Genome conservatism of phiKMV-like bacteriophages (T7 supergroup) active against Pseudomonas aeruginosa. Genetika, 42: 33-38. (In Russian)
5. Castillo FJ, Bartell PF. 1974. Studies on the bacteriophage 2 receptors of Pseudomonas aeruginosa. J Virol, 14: 904-909.
6. Castillo FJ, Bartell PF. 1976. Localization and functional role of the pseudomonas bacteriophage 2 depolymerase. J Virol, 18: 701-708.
7. Ceyssens PJ, Hertveldt K, Ackermann HW, Noben JP, Demeke M, Volckaert G, Lavigne R. 2008. The intron-containing genome of the lytic Pseudomonas phage LUZ24 resembles the temperate phage PaP3. Virology, 377: 233-238.
  doi: 10.1016/j.virol.2008.04.038
8. Ceyssens PJ, Miroshnikov K, Mattheus W, Krylov V, Robben J, Noben JP, Vanderschraeghe S, Sykilinda N, Kropinski AM, Volckaert G, Mesyanzhinov V, Lavigne R. 2009. Comp arative analysis of the widespread and conserved PB1-like viruses infecting Pseudomonas aeruginosa. Envi ron Microbiol, 11: 2874-2883.
  doi: 10.1111/emi.2009.11.issue-11
9. Ceyssens PJ, Glonti T, Kropinski NM, Lavigne R, Chanishvili N, Kulakov L, Lashkhi N, Tediashvili M, Merabishvili M. 2011. Phenotypic and genotypic variations within a single bacteriophage species. Virol J, 8: 134.
  doi: 10.1186/1743-422X-8-134
10. Ceyssens PJ, Minakhin L, Van den Bossche A, Yakunina M, Klimuk E, Blasdel B, De Smet J, Noben JP, Bläsi U, Severinov K, Lavigne R. 2014. Development of giant bacteriophage ΦKZ is independent of the host transcription apparatus. J Virol, 88: 10501-10510.
  doi: 10.1128/JVI.01347-14
11. Chaconas G, de Bruijn FJ, Casadaban MJ, Lupski JR, Kwoh TJ, Harshey RM, DuBow MS, Bukhari AI. 1981. In vitro and in vivo manipulations of bacteriophage Mu DNA: cloning of Mu ends and construction of mini-Mu's carrying selectable markers. Gene, 13: 37-46.
  doi: 10.1016/0378-1119(81)90041-X
12. Chanishvili N. 2012. Phage therapy-history from Twort and d'Herelle through Soviet experience to current approaches. Adv Virus Res, 83: 3-40.
  doi: 10.1016/B978-0-12-394438-2.00001-3
13. Cornelissen A, Hardies SC, Shaburova OV, Krylov VN, Mattheus W, Kropinski AM, Lavigne R. 2012. Complete genome sequence of the giant virus OBP and comparative genome analysis of the diverse ΦKZ-related phages. J Virol, 86: 1844-1852.
  doi: 10.1128/JVI.06330-11
14. Duckworth DH. 1976. ""Who discovered bacteriophage?"" Bacteriol Rev, 40: 793-802.
15. Eller MR, Vidigal PM, Salgado RL, Alves MP, Dias RS, da Silva CC, de Carvalho AF, Kropinski A, De Paula SO. 2014. UFV-P2 as a member of the LUZ24likevirus genus: a new overview on comparative functional genome analyses of the LUZ24-like phages. BMC Genomics, 15: 7.
  doi: 10.1186/1471-2164-15-7
16. Fehér T, Karcagi I, Blattner FR, Pósfai G. 2012, Bacteriophage recombineering in the lytic state using the lambda red recombinases. Microb Biotechnol, 5: 466-476.
  doi: 10.1111/mbt.2012.5.issue-4
17. Fortier LC Sekulovic O. 2013. Importance o f prophages to evolution and virulence of bacterial pathogens. Virulence, 4: 354-365.
  doi: 10.4161/viru.24498
18. Glonti T, Chanishvili N, Taylor PW. 2010. Bacteriophage-derived enzyme that depolymerizes the alginic acid capsule associated with cystic fibrosis isolates of Pseudomonas aeruginosa. J Appl Microbiol, 108: 695-702.
  doi: 10.1111/jam.2009.108.issue-2
19. Glukhov AS, Krutilina AI, Shlyapnikov MG, Severinov K, Lavysh D, Kochetkov VV, McGrath JW, de Leeuwe C, Shaburova OV, Krylov VN, Akulenko NV, Kulakov LA. 2012. Genomic analysis of Pseudomonas putida phage tf with localized single-strand DNA interruptions. PLoS One, 7: e51163.
  doi: 10.1371/journal.pone.0051163
20. Górski A, Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, Lobocka M, Fortuna W, Letkiewicz S, Zimecki M, Filby G. 2009. Bacteriophage therapy for the treatment of infections. Curr Opin Investig Drugs, 10: 766-774.
21. Groisman EA, Casadaban MJ. 1987. Cloning of genes from members of the family Enterobacteriaceae with mini-Mu bacteriophage containing plasmid replicons. J Bacteriol, 169: 687-693.
  doi: 10.1128/jb.169.2.687-693.1987
22. Hanlon GW, Denyer SP, Olliff CJ, Ibrahim LJ. 2001. Reduction in exopolysaccharide viscosity as an aid to bacteriophage penetration through Pseudomonas aeruginosa biofilms. Appl Environ Microbiol, 67: 2746-2753.
  doi: 10.1128/AEM.67.6.2746-2753.2001
23. Henry M, Lavigne R, Debarbieux L. 2013. Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections. Antimicrob Agents Chemother, 57: 5961-5968.
  doi: 10.1128/AAC.01596-13
24. d'Herelle FH. 1917. Sur un microbe invisible antagoniste des bacilles dysenteriques. C R Acad Sci, 165: 373-375. (In French)
25. Hertveldt K, Lavigne R, Pleteneva E, Sernova N, Kurochkina L, Korchevskii R, Robben J, Mesyanzhinov V, Krylov VN, Volckaert G. 2005. Genome comparison of Pseudomonas aeruginosa large phages. J Mol Biol, 2; 354: 536-545.
26. Holloway BW, Egan JB, Monk M. 1960. Lysogeny in Pseudomonas aeruginosa. Aust J Exp Biol Med Sci. 38: 321-329.
  doi: 10.1038/icb.1960.34
27. James CE, Fothergill JL, Kalwij H, Hall AJ, Cottell J, Brockhurst MA, Winstanley C. 2012. Differential infection properties of three inducible prophages from an epidemic strain of Pseudomonas aeruginosa. BMC Microbiol, 12: 216.
  doi: 10.1186/1471-2180-12-216
28. Jarrell K, Kropinski AM. 1977. Identification of the cell wall receptor for bacteriophage E79 in Pseudomonas aeruginosa strain PAO. J Virol, 23: 461-466.
29. Jenkins FJ, Casadaban MJ, Roizman B. 1985. Application of the mini-Mu-phage for target-sequence-specific insertional mutagenesis of the herpes simplex virus genome. Proc Natl Acad Sci U S A, 82: 4773-4777.
  doi: 10.1073/pnas.82.14.4773
30. Jeon J, Kim JW, Yong D, Lee K, Chong Y. 2012. Complete genome sequence of the bacteriophage YMC01/01/P52 PAE BP, which causeslysis of verona integron-encoded metallo-β-lactamase-producing, carbapenem-resistant Pseudomonas aeruginosa. J Virol, 86: 13876-13877
  doi: 10.1128/JVI.02730-12
31. Kaplan AM, Akhverdian VZ, Reulets MA, Krylov VN. 1988. Compatibility of transposable phages of Escherichia coli and Pseudomonas aeruginosa. I. Co-development of phages Mu and D3112 and integration of phage D3112 into RP4::Mu plasmid in Pseudomonas aeruginosa cells. Genetika, 24: 634-640. (In Russian)
32. Kim S, Rahman M, Kim J. 2012. Complete genome sequence of Pseudomonas aeruginosa lytic bacteriophage PA1O which resembles temperate bacteriophage D3112. J Virol, 86: 3400-3401.
  doi: 10.1128/JVI.07191-11
33. Kulakov LA, Ksenzenko VN, Shlyapnikov MG, Kochetkov VV, Del Casale A, Allen CC, Larkin MJ, Ceyssens PJ, Lavigne R. 2009. Genomes of ""phiKMV-like viruses"" of Pseudomonas aeruginosa contain localized single-strand interruptions. Virology, 391: 1-4.
  doi: 10.1016/j.virol.2009.06.024
34. Krylov VN, Shaburova OV. 2012. Factors Favoring Co-Evolution of Pseudomonas Aeruginosa and its Viruses in Microbial Communities of Infected Wounds Surfaces and Prospects for Phage Therapy. In: Pseudomonas Aeruginosa: Symptoms of Infection, Antibiotic Resistance and Treatment. Beningo M. Penha Escudeiro and Eduardo C. Baracho Marques. USA: NOVA Science Publishers. pp37-66.
35. Krylov VN, Zhazykov IZh. 1978. Pseudomonas bacteriophage phiKZ-possible model for studying the genetic control of morphogenesis. Genetika, 14: 678-685. (In Russian)
36. Krylov VN, Smirnova TA, Minenkova IB, Plotnikova TG, Zhazikov IZ, Khrenova EA. 1984. Pseudomonas bacteriophage phi KZ contains an inner body in its capsid. Can J Microbiol, 30: 758-762.
  doi: 10.1139/m84-116
37. Krylov V, Shaburova O, Krylov S and Pleteneva E. 2013. A Genetic Approach to the Development of New Therapeutic Phages to Fight Pseudomonas aeruginosa in Wound Infections. Viruses, 5: 15-53.
38. Krylov V, Pleteneva E, Shaburova O, Bourkaltseva M, Krylov S, Chesnokova E, Polygach O. Commo n Preconditions for Safe Phage Therapy of Pseudomonas aeruginosa Infections. 2014. Advances in Microbiology, 4: 766-773.
39. Krylov SV, Pleteneva EA, Burkal'tseva MV, Shaburova OV, Miroshnikov KA, Lavigne R, Cornelissen A, Krylov VN. 2011. Genome instability of Pseudomonas aeruginosa phages of the EL species: examination of virulent mutants. Genetika, 47: 183-189. (In Russian)
40. Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S, Abedon ST. 2010. Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol, 11: 69-86.
  doi: 10.2174/138920110790725401
41. Lavigne R, Burkaltseva MV, Robben J, Sykilinda NN, Kurochkina L P, Grymomprez B, Jonckx B, Krylov VN, Mesyanzhinov VV, Volckaert G. 2003. The genome of bacteriophage phiKMV, a T7-like virus infecting Pseudomonas aeruginosa. Virology, 312: 49-59.
  doi: 10.1016/S0042-6822(03)00123-5
42. Lindberg RB, Latta RL. 1974. Phage typing of Pseudomonas aeruginosa: clinical and epidemiologic considerations. J Infect Dis. 130: S33-S42.
  doi: 10.1093/infdis/130.Supplement.S33
43. Lu S, Le S, Tan Y, Zhu J, Li M, Rao X, Zou L, Li S, Wang J, Jin X, Huang G, Zhang L, Zhao X, Hu F. 2013. Genomi c and proteomic analyses of the terminally redundant genome of the Pseudomonas aeruginosa phage PaP1: establishment of genus PaP1-like phages. PLoS One, 8: e62933.
  doi: 10.1371/journal.pone.0062933
44. Marinelli LJ, Hatfull GF, Piuri M. 2012. Recombineering: A powerful tool for modification of bacteriophage genomes. Bacteriophage, 2: 5-14.
  doi: 10.4161/bact.18778
45. Maura D, Debarb ieux L. 2011. Bacteriophages as twenty-first century antibacterial tools for food and medicine. Appl Microbiol Biotechnol, 90: 851-859.
  doi: 10.1007/s00253-011-3227-1
46. McCallin S, Alam Sarker S, Barretto C, Sultana S, Berger B, Huq S, Krause L, Bibiloni R, Schmitt B, Reuteler G, Brüssow H. 2013.Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects. Virology, 443: 187-196.
  doi: 10.1016/j.virol.2013.05.022
47. Mesyanzhinov VV, Robben J, Grymonprez B, Kostyuchenko VA, Bourkaltseva MV, Sykilinda NN, Krylov VN, Volckaert G. 2002. The Genome of Bacteriophage phiKZ of Pseudomonas aeruginosa. J Mol B iol, 317: 1-19.
  doi: 10.1006/jmbi.2001.5396
48. Miao EA, Miller SI. 1999. Bacteriophages in the evolution of pathogen-host interactions. Proc Natl Acad Sci U S A, 96: 9452-9454.
  doi: 10.1073/pnas.96.17.9452
49. Morello E, Saussereau E, Maura D, Huerre M, Touqui L, Debarbieux L. 2011. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS One, 6: e16963.
  doi: 10.1371/journal.pone.0016963
50. Murray NE. 2006. The impact of phage lambda: from restriction to recombineering. Biochem Soc Trans, 34: 203-207.
  doi: 10.1042/BST0340203
51. Perepanova TS, Darbeeva OS, Kotliarova GA, Kondrat'eva EM, Maĭskaia LM, Malysheva VF, Baĭguzina FA, Grishkova NV. 1995. The efficacy of bacteriophage preparations in treating inflammatory urologic diseases. Urol Nefrol (Mosk), 5: 14-17. (In Russian)
52. Pleteneva EA, Shaburova OV, Sykilinda NN, Miroshnikov KA, Krylov SV, Mesianzhinov VV, Krylov VN. 2008. Study of the diversity in a group of phages of Pseudomonas aeruginosa species PB1 (Myoviridae) and their behavior in adsorbtion-resistant bacterial mutants. Genetika, 44: 185-194. (In Russian)
53. Pleteneva EA, Shaburova OV, Krylov VN. 2009. A formal scheme of adsorptional receptors in Pseudomonas aeruginosa and possibilities for its practical implementation. Genetika, 45: 43-49. (In Russian)
54. Pleteneva EA, Krylov SV, Shaburova OV, Burkal'tseva MV, Miroshnikov KA, Krylov VN. 2010. Pseudolysogeny of Pseudomonas aeruginosa bacteria infected with phiKZ-like bacteriophages. Genetika, 46: 26-32. (In Russian)
55. Pleteneva EA, Burkal'tseva MV, Shaburova OV, Krylov SV, Pechnikova EV, Sokolova OS, Krylov VN. 2011. TL, the new bacteriophage of Pseudomonas aeruginosa and its application for the search of halo-producing bacteriophages. Genetika, 47: 5-9. (In Russian)
56. Plotnikova TG, Kulakov LA, Eremenko EN, Fedorova TV, Krylov VN. 1982. Expression of the genome of Mu-like phage D3112 specific for Pseudomonas aeruginosa in Escherichia coli and Pseudomonas putida cells. Genetika, 18: 1075-1084. (In Russian)
57. Plotnikova TG, Ianenko AS, Kirsanov NB, Krylov VN. 1983. Transposition of the phage D3112 genome in Escherichia coli cells. Genetika, 19: 1611-1915. (In Russian)
58. Rodríguez-Rubio L, Martínez B, Donovan DM, Rodríguez A, García P. 2012. Bacteriophage virion-associated peptidoglycan hydrolases: potential new enzybiotics. Critical Reviews in Microbiology, 39: 427-434.
59. Sambrook J, Fr itsch EF, Maniatis T, 1989. Molecular Cloning: A Laboratory Manual. Second edition. New York: Cold Spring Harbor Press. V.3, Apendix A.1-4
60. Schmelcher M, Tchang VS, Loessner MJ. 2011. Domain shuffling and module engineering of Listeria phage endolysins for enhanced lytic activity and binding affinity. Microb Biotechnol, 4: 651-662.
  doi: 10.1111/mbt.2011.4.issue-5
61. Schmelcher M, Donovan DM, Loessner MJ. 2012. Bacteriophage endolysins as novel antimicrobials. Future Microbiol, 7: 1147-1171.
  doi: 10.2217/fmb.12.97
62. Seeger K, Saunders D, Harris D, Parkhill J, Hancock RE, Brinkman FS, Levesque RC. 2009. Newly introduced genomic prophage islands are critical determinants of in vivo competitiveness in the Liverpool Epidemic Strain of Pseudomonas aeruginosa. Genome Res, 19: 12-23.
63. Sokolova OS, Shaburova OV, Pechnikova EV, Shaytan AK, Krylov SV, Kiselev NA, Krylov VN. 2014. Genome packaging in EL and Lin68, two giant phiKZ-like bacteriophages of P. aeruginosa. Virology, 468-470: 472-478.
  doi: 10.1016/j.virol.2014.09.002
64. Tan Y, Zhang K, Rao X, Jin X, Huang J, Zhu J, Chen Z, Hu X, Shen X, Wang L, Hu F. 2007. Whole genome sequencing of a novel temperate bacteriophage of P. aeruginosa: evidence of tRNA gene mediating integration of the phage genome into the hostbacterial chromosome. Cell Microbiol, 9: 479-491.
65. Thomas JA, Rolando MR, Carroll CA, Shen PS, Belnap DM, Weintraub ST, Serwer P, Hardies SC. 2008. Characterization of Pseudomonas chlororaphis myovirus 201varphi2-1 via genomic sequencing, mass spectrometry, and electron microscopy. Virology, 376: 330-338.
  doi: 10.1016/j.virol.2008.04.004
66. Thomason LC, Oppenheim AB, Court DL. 2009. Modifying bacteriophage lambda with recombineering. Methods Mol Biol, 501: 239-251.
  doi: 10.1007/978-1-60327-164-6
67. Twort FW. 1915. An investigation on the nature of ultra-microscopic viruses. Lancet, ii: 1241-1243.
68. Winstanley C, Langille MG, Fothergill JL, Kukavica-Ibrulj I, Paradis-Bleau C, Sanschagrin F, Thomson NR, Winsor GL, Quail MA, Lennard N, Bignell A, Clarke L, Seeger K, Saunders D, Harris D, Parkhill J, Hancock RE, Brinkman FS, Levesque RC. 2009. Newly introduced genomic prophage islands are critical determinants of in vivo competitiveness in the Liverpool Epidemic Strain of Pseudomonas aeruginosa. Genome Res, 19: 12-23.
69. Wright A, Hawkins CH, Anggård EE, Harper DR. 2009. A controlled cl inical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol, 34: 349–357
  doi: 10.1111/coa.2009.34.issue-4
Proportional views